Your Prescription Is Late and You Are Not Alone

Jenny Carrick calls her pharmacy every month like it is a bet she does not want to place. Will her estrogen patch be in stock? Carrick, a 55-year-old marketing director from the Sacramento area, spent years getting her hormone therapy right. She pushed through misdiagnoses and antidepressant trial periods before her doctor finally prescribed transdermal estradiol. Now that it works, she cannot count on getting it. Carrick told USA Today in February 2026 that she orders her refill the moment her insurance allows it and still spends days hoping the pharmacist finds a box somewhere.

She is one of hundreds of thousands of women caught in a global menopause treatment shortage that has no single cause and no quick fix. The crunch hits different countries in different ways. The UK cannot keep estrogel and utrogestan on shelves. Australia has patch shortages that the Therapeutic Goods Administration says will stretch through all of 2025 and likely beyond. In the United States, the FDA’s removal of the black-box warning on estrogen therapy in November 2025 triggered a demand surge that manufacturers like Sandoz and Amneal cannot keep up with. If you are struggling to fill your HRT prescription, you need to know what caused this mess and exactly what moves to make next.

What Caused the Menopause Treatment Shortage

The simplest explanation is the most uncomfortable one: for the first time in twenty years, millions of women want menopause treatment, and the system was not built for that. Demand for HRT has risen steadily since the late 2010s as awareness campaigns, social media conversations, and updated clinical guidelines pushed women to seek care instead of suffering silently. The UK saw a 40 percent increase in HRT prescriptions after Davina McCall’s BBC documentaries aired between 2022 and 2024. In the US, prescriptions for estrogen patches jumped sharply after the FDA reversed its decades-old position and removed the black-box warning from estrogen products in November 2025.

Dr. Nora Lansen, chief medical officer of Elektra Health, told NPR in March 2026 that demand has been building for four to five years as both clinicians and patients revisit the data. The Women’s Health Initiative study scared a generation off hormone therapy starting in 2002. That fear is finally fading, and the result is a patient population that grew faster than manufacturers expected. Sandoz, one of the largest producers of estradiol patches, acknowledged in a statement that it is struggling to meet global demand. The company is working to increase capacity but has not given a timeline for when supply will catch up.

Compounding the demand surge are real manufacturing constraints. Transdermal patches are not simple to produce at scale. The adhesive matrix, the controlled-release membrane, and the precise hormone distribution require specialized production lines that cannot be spun up overnight. Amneal Pharmaceuticals, another major patch manufacturer, confirmed to NPR that it has seen a significant increase in demand since the FDA announcement. The company is meeting its existing contracts but cannot take on new volume fast enough.

The UK Crisis: Estrogel, Utrogestan, and the HRT PPC

The UK situation has its own flavor. Shortages of estrogel and utrogestan have been intermittent since 2022 but remain unresolved as of early 2026. The British Menopause Society stopped publishing regular HRT supply updates because the situation shifts too frequently for a static document. Manufacturer-specific medicine supply notifications from the Department of Health and Social Care now serve as the real-time source, but patients rarely know where to find them.

The UK government did take one meaningful step. The HRT Prescription Prepayment Certificate, introduced at £19.30 per year, covers all HRT prescriptions regardless of how many items you need. As of November 2024, more than 500,000 women had used the certificate, saving up to £220 annually. Karin Smyth MP confirmed in a November 2024 parliamentary response that the government tracks over 70 stocked HRT products. The problem is that stocked does not mean available at your local pharmacy on the day you need it. A product can be manufactured and in the distribution system but still take weeks to reach a Boots or LloydsPharmacy in a specific area.

Nick Timothy MP raised the issue in Parliament in November 2024, asking directly about HRT availability. The government’s response confirmed improvements but also acknowledged that some products still face supply issues due to increased demand. For a woman standing in a pharmacy in Manchester or Bristol being told estrogel is out until next month, that acknowledgment offers little comfort.

The Australian PBS and TGA Reality

Australia has a different problem. The country’s Pharmaceutical Benefits Scheme lists estradiol patches from Sandoz (Estradot) and Juno Pharmaceuticals, and both have been in shortage since 2024. The Therapeutic Goods Administration issued a formal update in December 2024 confirming that shortages of Estradot and Estraderm MX patches would continue through June and December 2025. That timeline has now passed, and the shortages persist into 2026.

The Australian government responded in February 2025 by adding new menopausal hormone therapy products to the PBS for the first time in more than two decades. The Australasian Menopause Society called it a breakthrough, but the practical effect is limited. New listings take months to reach pharmacy shelves, and the TGA explicitly advised that prescribing should be limited to existing patients to preserve supply. That means new patients, or women who recently realized their symptoms are hormonal, face the hardest access barriers.

Australia’s Parliamentary Budget Office estimated in May 2025 that new federal funding for menopause treatments would cost roughly $330 million over the forward estimates period. The money is real, but the supply chain takes longer to fix than a budget line item.

The US Free-for-All: Patches, Gel, and the $300 Workaround

In the United States, the shortage plays out like a monthly scavenger hunt. Abbie Schiller, a 53-year-old goal coach in Los Angeles, told USA Today she spent seven hours in one month calling large chains and small family pharmacies to find her estrogen patch. Some women drive 45 miles to pick up a single box. Others switch from a generic patch to a brand-name version that costs $300 a month and is not covered by insurance, because that is the only option the pharmacy has.

The American Society of Health-System Pharmacists lists multiple estrogen products with active or recent shortages. CVS confirmed to NPR that manufacturers cannot provide sufficient supply of several estrogen products. The company’s pharmacists check other locations for customers, but that only works when a box exists somewhere in the system. When it does not, the customer walks out empty-handed.

Dr. Heather Hirsch, a physician and founder of The Collaborative concierge practice in Boston, advises patients to try online pharmacies, which she says have not experienced the same level of disruption. She also recommends switching to alternatives: daily estradiol gel, the estradiol ring (Femring), or the estrogen spray (Evamist). Oral estrogen pills remain an option, though some women prefer transdermal delivery because it bypasses first-pass liver metabolism and carries a lower blood-clot risk.

What to Do When Your Medication Is Out of Stock

You have options, and they are better than rationing your patches. Do not cut your patches in half or stretch a two-week supply to four weeks. That creates unstable hormone levels and makes symptoms worse. Here is what actually works.

Pharmacy-Level Fixes

Switch pharmacies. This is the simplest fix and the one most women try first. But do not just call another location of the same chain. Try a completely different type of pharmacy. Mail-order pharmacies through your insurance often have different stock. Independent compounding pharmacies may have bioidentical estradiol on hand even when CVS and Walgreens do not. Hospital outpatient pharmacies sometimes carry stock that retail chains cannot access.
Switch formulations, not hormones. If your estradiol patch is unavailable, ask your doctor to switch you to estradiol gel, spray, or the vaginal ring. These are not identical, but they deliver the same hormone at comparable doses. The Femring releases estradiol acetate over 90 days, which means one prescription covers three months without monthly pharmacy anxiety. Estrogel and Divigel come in metered-dose packets that you apply to your arm or thigh daily.
Switch brands within the same formulation. Insurance may not cover a brand-name patch when a generic exists, but some pharmacies have one and not the other. If Mylan’s generic estradiol is out but the Sandoz brand is in stock, ask your doctor if a brand-name prescription is acceptable. The trade-off is cost. Brand-name patches can run $200 to $300 monthly without insurance coverage.
Check the BMS HRT Preparations Guide if you are in the UK. The British Menopause Society published a comprehensive list of equivalent HRT alternatives organized by delivery method. Take this guide to your GP or pharmacist and ask which alternatives are available in your area. The January 2024 edition is the most recent full publication, but it remains the best reference tool available.
Use the UK HRP PPC to keep costs down. If you are in the UK and not yet using the HRT Prescription Prepayment Certificate, get it. One payment of £19.30 covers unlimited HRT prescriptions for twelve months. That alone removes the financial barrier to switching products, because you are not paying per item.

The Online Pharmacy Option

Online pharmacies have emerged as the most reliable source for HRT during the shortage. Jennifer Skoog Mondesir, a personal trainer in Jersey City, told NPR that switching to an online pharmacy solved her patch problem entirely. She no longer calls around. Her medication arrives by mail on schedule.

US-based online menopause clinics like Midi Health, Evernow, and Alloy handle prescribing and delivery as a single service. They often have their own supply agreements with manufacturers, bypassing the retail pharmacy system entirely. The same applies in the UK with services like The Menopause Charity’s pharmacy directory, which lists online dispensaries that stock alternatives when high street pharmacies run out.

How Long Will This Last

The honest answer is that nobody knows. Sandoz and Amneal are both expanding production capacity, but building pharmaceutical manufacturing lines takes eighteen months at minimum. The FDA’s black-box removal created a permanent demand shift, not a temporary spike. The Menopause Society now estimates that HRT usage among eligible women in the US could double within three years as awareness spreads. If that projection holds, current production capacity will remain inadequate.

Australia’s TGA has been the most transparent about timelines. Their December 2024 update projected shortages through mid-2025. Those projections expired without resolution. The Australian government’s new PBS listings and $330 million funding commitment will help, but structural supply takes longer to fix than demand-side policy.

The UK’s position is slightly better because the market has more alternatives. With over 70 stocked HRT products and the PPC reducing cost barriers, women who are willing to switch formulations can usually find something. The challenge is that every switch requires a GP appointment, and GP appointment wait times in the UK add another layer of frustration.

For the immediate future, the best strategy is flexibility. If you can switch between patches, gel, spray, and rings as availability shifts, you will stay treated. If you insist on one specific product, you will spend your month on the phone. That is not fair, but it is the reality of the menopause treatment shortage in 2026.